返回
TransThera Sciences (Nanjing), Inc.（02617.HK）價格
02617.HK 股價走勢圖
TRANSTHERA-B (02617.HK)
TransThera Sciences (Nanjing), Inc.
HK$0
0%
$0
休市： Jan 29, 16:00:00 HKT
暫無資料Follow-Up Questions
TransThera Sciences (Nanjing), Inc. 的關鍵財務報表是什麼？
02617.HK 的關鍵財務比率是什麼？
TransThera Sciences (Nanjing), Inc. 的收入按細分市場或地理位置如何劃分？
TransThera Sciences (Nanjing), Inc. 是否盈利？
TransThera Sciences (Nanjing), Inc. 有負債嗎？
TransThera Sciences (Nanjing), Inc. 的流通股有多少？
關鍵數據
前收市價
--
開盤價
--
當日範圍
-
52週區間
-
交易量
--
平均成交量
1.7M
每股盈餘 (TTM)
-0.66
股息收益率
--
市值
--
什麼是 TRANSTHERA-B？
TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.